Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe Asthma

This Phase 2 study, sponsored by Eli Lilly and Company, is currently recruiting participants to evaluate the safety and efficacy of brenipatide in adults with uncontrolled moderate-to-severe asthma. The trial will compare different dose levels of brenipatide against a placebo. A total of 531 participants are estimated to enroll, with the study spanning approximately 65 weeks, including screening, treatment, and follow-up periods. The primary outcome measure is the annualized asthma exacerbation rate over 52 weeks of treatment. The study began on October 22, 2025, with a primary completion date set for April 2028. This trial aims to provide insights into the potential benefits of brenipatide for asthma management.